A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV-CLS-7262 in Subjects With Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension

Study Purpose:

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is a 48-week, 2-part study. Part 1 will be a 4-week, randomized, double-blind, placebo-controlled study; Part 2 will be a 44-week active treatment extension (ATE) during which all subjects will receive ABBV-CLS-7262.

Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.

Study Status:



ALS , Amyotrophic Lateral Sclerosis

Study Type:


Type of Intervention:


Intervention Name:

ABBV-CLS-7262, Placebo




Phase 1

Study Chair(s)/Principal Investigator(s):


Clinicaltrials.gov ID:


Neals Affiliated?


Coordinating Center Contact Information

Calico Call Center / email hidden; JavaScript is required / 1-844-463-2423

Study Sponsor:

Calico Life Sciences LLC

Participant Duration:

48 weeks

Estimated Enrollment:


Estimated Study Start Date:

09 / 22 / 2021

Estimated Study Completion Date:

05 / 01 / 2023

Posting Last Modified Date:

06 / 22 / 2022

Date Study Added to neals.org:

07 / 02 / 2021

Minimum Age:

18 Years

Maximum Age:

80 Years

Can participants use Riluzole?


Inclusion Criteria:

- Must have an identified, reliable caregiver

- Confirmed diagnosis of Familial ALS or Sporadic ALS

- First ALS symptoms occurred ≤36 months before screening

- Able to swallow solids

- No known active COVID-19 infection at screening

- Vital capacity ≥50% predicted value (for sex, age, ethnic origin, and height) at screening

- Subjects must be a) naïve to, or b) off riluzole (Rilutek), or c) on a stable dose >30 days prior to Baseline visit to enter study

- Subjects must be a) naïve to, or b) off edaravone (Radicava), or c) have completed 2 treatment cycles prior to the Baseline visit.

Exclusion Criteria:

- History of dementia/severe cognitive problems at screening

- Use of riluzole (Rilutek®) if dose has NOT been stable for > 30 days prior to Baseline visit

- History of clinically significant medical conditions (other than ALS) or any other reason, including any physical, psychological, or psychiatric condition that, in the opinion of the Investigator, would compromise the safety or interfere with the subject's participation in the study, or would make the subject an unsuitable candidate to receive study drug, or would put the subject at risk by participating in the study.

- History of abnormal screening laboratory or imaging results that, in the opinion of the Investigator, are indicative of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, infectious, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, neurologic, and/or other major disease that would preclude administration of ABBV-CLS-7262.

- If female, is known to be pregnant, breastfeeding, considering becoming pregnant, or donating/banking eggs during the study or within 30 days or >5 half-lives (whichever is longer) after the last dose of study drug

- If male, plans to donate sperm or father a child during the study or within 30 days after the last dose of study drug.

- Known to have received any investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.

- History of ABBV-CLS-7262 use prior to participation in this study

- Recent (within 6 months prior to Screening) history of drug or alcohol abuse

- Previous participation in a stem cell clinical study

- Current or anticipated use of diaphragmatic pacing during the study period

- Tracheostomy or use of non-invasive ventilatory support ≥22 hours a day

UC Irvine Health ALS and Neuromuscular Center | Recruiting

Principal Investigator : Namita Goyal

Irvine, California 92868
United States

Forbes Norris MDA/ALS Research and Treatment Center | Recruiting

Principal Investigator : Jonathan Katz

San Francisco, California 94109
United States

Mayo Clinic | Recruiting

Principal Investigator : Bjorn Oskarsson

Jacksonville, Florida 32224
United States

Healey & AMG Center for ALS Research | Recruiting

Darshana Hari / 617-643-3530 / email hidden; JavaScript is required

Max Higgins / 617 643-2522 / email hidden; JavaScript is required

Principal Investigator : Doreen Ho

Boston, Massachusetts 02114
United States

Mayo Clinic | Recruiting

Principal Investigator : Nathan Staff

Rochester, Minnesota 55905
United States

University of Calgary - Heritage Medical Research Clinic | Recruiting

Principal Investigator : Rodney Li Pi Shan

Calgary, Alberta T2V1P9

University of Alberta | Recruiting

Principal Investigator : Wendy Johnston

Edmonton, Alberta T6G 2G3

Stan Cassidy Centre for Rehabilitation | Recruiting

Principal Investigator : Colleen O'Connell

Fredericton, New Brunswick E38 0C7

London Health Sciences Centre | Recruiting

Principal Investigator : Christen Shoesmith

London, Ontario N6A585

Sunnybrook Research Institute | Recruiting

Principal Investigator : Lorne Zinman

Toronto, Ontario M4N 3M5

Centre Hospitalier de l'Universite de Montreal (CHUM) | Recruiting

Principal Investigator : Genevieve Matte

Montreal, Quebec H2L 4M1

Montreal Neurological Institute and Hospital | Recruiting

Principal Investigator : Angela Genge

Montreal, Quebec H3A 2B4